In October 2024, the Ministry of Health of the Russian Federation released the Clinical Guidelines for Non-alcoholic Fatty Liver Diseases developed by professional organizations such as the Liver Research Society, the Gastroenterology Association, and the Endocrinology Association, and approved by the Scientific and Practical Council of the Ministry of Health. “For NAFLD (NASH) patients with moderate to severe elevated ALT, it is recommended to prescribe a dose of 75-150mg/day of Bicyclol for 24 weeks to reduce disease activity” (Evidence level I, Recommendation B). Bicyclol was registered and marketed in Russia in August 2015, and has been included in Guidelines for Diagnosis, Treatment, and Prevention of Viral Hepatitis in Armed Forces, Drug-Induced Liver Injuries (Clinical Guidelines for Physicians) and Clinical Guideline...

In September 2024, Journal of Practical Hepatology and Journal of Clinical Hepatology (both are listed as the key magazine of China technology), published the Multidisciplinary Expert Consensus on the Prevention and Treatment of Inflammatory Liver Injury with Bicyclol. Inflammatory liver injury is the initiating factor for various chronic liver diseases. The diagnosis and treatment of liver injury often require multidisciplinary discussions and joint decision-making. The preparation of the Consensus is organized by the Hepatology Group of the Chronic Disease Management Branch of the China Medicinal Biotechnology Association. Domestic experts from relevant disciplines, based on the guidelines/consensus/clinical pathways and evidence-based medicine for liver disease diagnosis and treatment with reference to the clinical practice in China, summarize the pro...

On April 26th, 2024, the Chinese Society of Clinical Oncology (CSCO) Guidelines Conference was held in Jinan. Experts and scholars from various fields of oncology across the country gathered to focus on the latest research progress, discuss clinical practice hotspots, and clarify ideas and directions for the high-quality development of the discipline. At this conference, CSCO released a total of 32 oncology diagnosis and treatment guidelines, of which 31 were revised and updated editions. The only firstly published one was the Guidelines for Diagnosis and Management of Anti-tumor Drug-induced Liver Injury. This is another drug safety guideline launched by the Antitumor Drug Safety Management Expert Committee of CSCO, following adverse reactions such as thrombocytopenia, anemia, and venous thrombosis related to tumor treatment. It aims to address the...